In US JDM patients with anti-Sp4/CCAR1 we observed slightly higher rates of Raynaud’s, no cutaneous ulceration and lower levels of AST compared with anti-TIF1γ positive US patients without anti-TIF1γ-associated autoantibodies; however, the differences were not statistically significant due to the small number of anti-Sp4/CCAR1 positive individuals. This evidence concerns the gene TRIM33 and juvenile dermatomyositis.